Entrada Therapeutics (TRDA) executive compensation, 2026 proxy

Dipal Doshi, Chief Executive Officer, was paid $3.8M in 2025, down 1% from $3.9M the year before.

Filed
April 24, 2026
Annual meeting
June 10, 2026
Pay year
2025
Named executives
3
CEO total pay
$3.8M-1% vs prior year
CEO pay in equity
74%$2.8M in awards
CEO Target Bonus
55%Percentage of base salary
Bonus Achievement
100%Corporate performance achievement level
CEO Base Salary
$635,000For fiscal year 2025

How Doshi was paid

$3.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary17%Stock awards36%Option awards38%Non-equity incentive9%All other compensation0%

Named executive officers

ExecutiveTotal
Dipal DoshiChief Executive Officer$3,837,737
Natarajan Sethuraman Ph. D.President of Research and Development$2,254,315
Nathan J. DowdenPresident and Chief Operating Officer$2,223,497

What changed and why

  • $3.8MChief Executive Officer Dipal Doshi received total compensation of $3,837,737 in 2025, representing a slight decrease from 2024.
  • $635KBase salaries for named executive officers were set at $635,000 for Mr. Doshi, $520,000 for Dr. Sethuraman, and $499,200 for Mr. Dowden.
  • 100%Annual non-equity incentive plan bonuses were paid out based on corporate performance metrics achieved at 100% of target.
  • 55%Target bonus opportunities were set at 55% of base salary for the CEO and 45% for the other named executive officers.
  • Equity awards consisting of stock options and restricted stock units were granted to align executive interests with long-term performance.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.